Orthofix Medical Management

Management criteria checks 0/4

Orthofix Medical's CEO is Massimo Calafiore, appointed in Jan 2024, has a tenure of less than a year. directly owns 0.003% of the company’s shares, worth €12.61K. The average tenure of the management team and the board of directors is 1.3 years and 1.3 years respectively.

Key information

Massimo Calafiore

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.003%
Management average tenure	1.3yrs
Board average tenure	1.3yrs

Recent management updates

Recent updates

CEO

Massimo Calafiore (51 yo)

less than a year

Tenure

Mr. Massimo Calafiore is President, CEO & Director of Orthofix Medical Inc. from January 8, 2024 and as Interim President of Global Spine from January 10, 2024. Mr. Massimo Calafiore was the Chief Executiv...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kimberley Elting	President of Global Orthopedics	1.3yrs	US$3.55m	0.23% $ 1.1m
Geoffrey Gillespie	VP & Corporate Controller	3yrs	US$887.05k	0.0051% $ 24.2k
Massimo Calafiore	President	less than a year	no data	0.0027% $ 12.6k
Julie Andrews	Chief Financial Officer	less than a year	no data	no data
Roberto Donadello	Senior Vice President of Global Operations	4.3yrs	no data	no data
Dan Yarbrough	Vice President of Investor Relations	no data	no data	no data
Jill Mason	Interim Chief Ethics & Compliance Officer and VP of Corporate Counsel	no data	no data	no data
J. Cedron	Chief Legal Officer & Corporate Secretary	less than a year	no data	no data
Lucas Vitale	Chief People & Business Operations Officer	less than a year	no data	no data
Ehab Esmail	Senior Vice President of Global Quality	5.3yrs	no data	no data
Tyler Lipschultz	President of Global Biologics	1.3yrs	no data	no data
Beau Standish	President of Global Enabling Technologies	no data	no data	no data

1.3yrs

Average Tenure

51yo

Average Age

Experienced Management: OM2's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Massimo Calafiore	President	less than a year	no data	0.0027% $ 12.6k
John Henneman	Independent Director	1.3yrs	US$355.42k	0.092% $ 434.7k
Stuart Essig	Independent Director	1.3yrs	US$355.42k	0.51% $ 2.4m
Catherine Burzik	Independent Chair of the Board	2.9yrs	US$2.62m	0.21% $ 1.0m
James Hinrichs	Independent Director	10.1yrs	US$388.75k	0.12% $ 588.8k
Alan Bazaar	Independent Director	less than a year	US$300.00k	no data
Jason Hannon	Independent Director	3.9yrs	US$376.25k	0.0052% $ 24.6k
Charles Kummeth	Independent Director	less than a year	US$300.00k	0.040% $ 189.5k
Michael Finegan	Independent Director	less than a year	US$300.00k	no data
Michael Paolucci	Independent Director	8.2yrs	US$376.25k	0.025% $ 119.3k
Shweta Maniar	Independent Director	1.3yrs	US$355.42k	0.015% $ 72.3k
Wayne Burris	Independent Director	less than a year	US$539.70k	0.017% $ 80.6k

1.3yrs

Average Tenure

60yo

Average Age

Experienced Board: OM2's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Orthofix Medical Management

Management criteria checks 0/4

Key information

Recent management updates

Orthofix Medical Inc., Annual General Meeting, Jun 18, 2024

Orthofix Medical Inc. Appoints Andres Cedron as New Chief Legal Officer

Orthofix Medical Inc. Announces Board Resignation

Orthofix Medical Inc. Appoints Lucas Vitale as Chief People and Business Operations Officer

Orthofix Medical Inc. Names Massimo Calafiore as President and Member of the Board of Directors Effective Immediately

Orthofix Medical Inc. Appoints Julie Andrews as Chief Financial Officer

Recent updates

Orthofix Medical Inc., Annual General Meeting, Jun 18, 2024

Orthofix Medical Inc. to Report Q1, 2024 Results on May 07, 2024

Orthofix Medical Inc. Appoints Andres Cedron as New Chief Legal Officer

New minor risk - Profitability

Orthofix Medical Inc. Announces Board Resignation

Orthofix Medical Inc. Appoints Lucas Vitale as Chief People and Business Operations Officer

Full year 2023 earnings released: US$4.12 loss per share (vs US$0.98 loss in FY 2022)

Orthofix Medical Inc. Provides Earnings Guidance for the Year 2024

Orthofix Medical Inc. to Report Q4, 2023 Results on Mar 05, 2024

Orthofix Medical Inc. Names Massimo Calafiore as President and Member of the Board of Directors Effective Immediately

Orthofix Medical Inc. Appoints Julie Andrews as Chief Financial Officer

Orthofix Announces Publication of New Data Supporting Use of PEMF Stimulation in Lumbar Spine Fusion Procedures for Patients at Risk of Pseudarthrosis

Orthofix Medical Inc. Announces Board Changes

Orthofix Medical Inc. Appoints Massimo Calafiore as Chief Executive Officer, Effective in Early 2024

Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Third quarter 2023 earnings released: US$0.78 loss per share (vs US$0.53 loss in 3Q 2022)

Orthofix Medical Inc. Announces Full Commercial Launch of the Waveform L Interbody System for Lateral Lumbar Fusion Procedures

Orthofix Medical Inc. to Report Q3, 2023 Results on Nov 08, 2023

Orthofix Medical Inc. Announces 510k Clearance and Full Commercial Launch of OsteoCove, an Advanced Bioactive Synthetic Graft for Use in Spine and Orthopedic Procedures

Orthofix Medical Inc. Announces First Patient Procedures and Full Commercial Launch of the Galaxy Fixation Gemini System and Expanded Sterile Kit Offerings for Orthopedic Trauma Procedures

Independent Director recently bought €95k worth of stock

Orthofix Medical Inc. Announces Management Appointments

Orthofix Medical Inc. Announces Management Changes

Second quarter 2023 earnings released: US$1.07 loss per share (vs US$0.12 profit in 2Q 2022)

Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Orthofix Medical Inc. to Report Q2, 2023 Results on Aug 08, 2023

Orthofix Medical Inc. Introduces New Phantom and Tornado Hins for Truelok Ring Fixation Systems

Orthofix Medical Inc. Announces Changes to Board of Directors

Orthofix Medical Inc Announces the Full Commercial Launch of WaveForm A 3D Printed Anterior Lumbar Interbody

Orthofix Medical Inc. Announces First Presentation of Seven-Year Outcome Data for the M6-C Artificial Cervical Disc with Other Clinical and Scientific Abstracts At the Isass Annual Meeting

President of Global Spine Business recently sold €146k worth of stock

First quarter 2023 earnings released: US$1.71 loss per share (vs US$0.22 loss in 1Q 2022)

Orthofix Medical Inc. Revises Sales Guidance for the Year 2023

Full year 2022 earnings released: US$0.98 loss per share (vs US$1.95 loss in FY 2021)

High number of new directors

Orthofix Announces Full Commercial Launch and First Patient Cases of Mariner Deformity System

Orthofix Medical Inc. Provides Unaudited Preliminary Net Sales Results Fourth Quarter and Full Year Ended December 31, 2022

Orthofix Medical Inc. Announces CFO Changes

Orthofix Medical Inc. Announces Publication of Data Demonstrating the Clinical Benefits of Trinity Elite Cellular Bone Allograft in Lumbar Fusion Procedures

Two unknown private equity fund sponsors submitted a non-binding indication of interest to acquire Orthofix Medical Inc. (NasdaqGS:OFIX) for approximately $460 million.

Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

High number of new directors

Third quarter 2022 earnings released

Orthofix Medical Inc. Provides Financial Guidance for the Full Year 2022

Orthofix Medical Inc. to Report Q3, 2022 Results on Nov 03, 2022

Orthofix Announces First Patient Implants with Legacy Demineralized Bone Matrix for Spine, Pelvic and Extremities Procedures

Orthofix Medical Inc. (NasdaqGS:OFIX) entered into a definitive agreement to acquire SeaSpine Holdings Corporation (NasdaqGS:SPNE) for approximately $280 million in a merger of equals transaction.

Orthofix Medical Inc. (NasdaqGS:OFIX) entered into a definitive agreement to acquire SeaSpine Holdings Corporation (NasdaqGS:SPNE) for approximately $280 million in a merger of equals transaction.

Second quarter 2022 earnings released: EPS: US$0.12 (vs US$0.12 in 2Q 2021)

Orthofix Medical Inc. Revises Financial Guidance for the Full Year 2022

Orthofix Medical Inc. to Report Q2, 2022 Results on Aug 05, 2022

Orthofix Announces First Clinical Use of Virtuos Lyograft – A First-Of-Its-Kind, Shelf-Stable and Complete Autograft Substitute for Spine and Orthopedic Procedures

First quarter 2022 earnings released: US$0.22 loss per share (vs US$0.30 loss in 1Q 2021)

Food and Drug Administration Grants Pre-Market Approval for Orthofix Medical's AccelStim Bone Growth Stimulation Device

High number of new directors

Orthofix Medical Inc. Announces Management Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Orthofix Medical Inc. Provides Earnings Guidance for the Year 2022

Orthofix Medical Inc. Announces Full Market Launch of Opus BA

High number of new directors

Independent Director recently bought €55k worth of stock

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.24 profit in 3Q 2020)

Orthofix Announces Full Market Launch of Opus Mg Set – a Magnesium-based Settable Bone Void Filler for Orthopedic Procedures

Second quarter 2021 earnings released: EPS US$0.12 (vs US$0.96 loss in 2Q 2020)

Orthofix Medical Inc Raises Net Sales Guidance for the Year Ended December 31, 2021

Orthofix Medical Inc. Announces First Patient Implant in M6-C Artificial Cervical Disc Two-Level IDE Study

Orthofix Medical Inc. Announces Publication of Data Shows High Fusion Rate in Patients Treated with PEMF Therapy Using the Orthofix SpinalStim Device

Independent Director Alexis Lukianov has left the company

Orthofix Announces U.S. Launch and First Patient Implant of 3D-Printed FORZA Titanium PLIF Spacer System with Nanovate Technology